Advent of advanced technologies for treating cardiovascular disease is intensifying the size of cardiac pacing leads the market
The
purpose of a cardiac pacing lead is to get the pulse rate of the heart up to a
certain level. Usually, the patient has to be in a coma or at least out of
deep, cardiac sleep to have their cardiac activity measured. Once they are in a
comatose state then a cardiac pacing lead can be used to start or continue the
pumping action in the heart
Increasing
incidences of cardiovascular diseases around the globe are driving the growth
of the cardiac pacing leads the market. According to the U.S. Department of
Health & Human Services, about 655,000 Americans die from heart disease
each year—that’s 1 in every 4 deaths. Coronary heart disease is the most common
type of heart disease, killing 365,914 people in 2017. The economic burden of
the disease is propelling the growth of the cardiac
pacing leads market. Recently the outbreak of novel coronavirus has
severely affected the patients suffering from cardiac problems. Thus this has
again raised the demand for cardiac pacing leads. Furthermore, the growing
demand for various pacemaker implantations for enhancing patient outcomes is
further anticipated to accelerate the growth of the market.
North
America is projected to gain significant growth over the forecast period and
this is attributed to the high presence of the geriatric population which is
increasing prevalence of the cardiovascular disease. According to the Urban
Institute, the number of Americans ages 65 and older will more than double over
the next 40 years, reaching 80 million in 2040. The number of adults ages 85
and older, the group most often needing help with basic personal care, will
nearly quadruple between 2000 and 2040.
Key Developments:
1. In May 2020, Medtronic plc
announced results from late-breaking clinical trials evaluating the MyCareLink
Heart™ mobile app and the Micra® Transcatheter Pacing System (TPS), products
that provide needed care for patients and optimal management of their symptoms
– while reducing potential exposure between patients and their clinicians.
2. In March 2017, BIOTRONIK has
launched its smallest and lightest mr-conditional pacemakers and a new range of
Quadripolar CRT-Ps in Europe
3. In January 2020, Medtronic has
won FDA approval for its Micra AV — greatly expanding the number of people who
could potentially benefit from leadless pacemaker technology
4. In February 2020, Abbott has
announced it has received CE Mark for the new Gallant™ implantable cardioverter-defibrillator
(ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices

Comments
Post a Comment